Common Brand Name(s):Basaglar, Lantus, Lantus Solostar, Rezvoglar, Semglee, Toujeo SoloStar, Toujeo Max SoloStar Common Generic Name(s):insulin glargine Pronunciation:IN-su-lin GLAR-jeen Drug Classes:antidiabetic, long-acting insulin Availability:prescription only, generic available ...
Generic name:insulin glargine[IN-su-lin-GLAR-gine] Other brand namesof insulin glargine include: Lantus,Lantus SoloStar Drug class:Insulin Medically reviewed byKaci Durbin, MD. Last updated on Aug 21, 2023. What is Lantus? Lantus is a man-made form of a hormone (insulin) that is produced...
Insulin was obtained from animal pancreatic tissues to treat diabetes before the availability of recombinant DNA (rDNA) technology. Often, the yield was low and potency was variable (∼25%). Toward the end of 1922, using isoelectric precipitation, animal insulin was able to be produced at high...
Insulin glargine is a long-acting human insulin analog to enhance glycemic control in adults and pediatric patients with type 1 diabetes and in adults with type 2 diabetes. Biosimilars are approved by the FDA as having highly similar safety and efficacy to the reference brand and "no clinically...
limited availability, and limited historical data, these models have not been used. Monkeys are also considered to have low predictivity for the immunogenic potential of insulin, thusimmunogenicitydata frompreclinical studiesare useful for data interpretation, but not useful for predicting human immunogenic...
Insulin Glargine (Monograph)Play pronunciation Brand names: Basaglar, Lantus, Soliqua 100/33 (combination), Toujeo Drug class: Long-acting Insulins ATC class: A10AB01 VA class: HS501 Chemical name: 21A-Glycine-30Ba-l-arginine-30Bb-l-arginine insulin (human) Molecular formula: C267H404N72O...
The availability of oral insulin would free millions of people with diabetes from the everyday burden of subcutaneous (SC) insulin injections. Furthermore, the convenience of oral insulin might facilitate earlier initiation of insulin therapy and better patient compliance leading to improved glucose cont...
half-unit insulin pens on the market [36]. Besides insulin pens commonly used for years tailored to deliver insulin 100 U/ml, progress in the development of higher concentrated insulin has led to new insulin pens for 200 U/ml (Humalog, Tresiba) and 300 U/ml (Toujeo/Glargine). Humalog ...
particularly relevant given the relatively narrow risk-to-benefit profile of sCT and the availability of other more efficacious therapeutic options[12,13]. A recent meta-analysis of data for sCT safety with the current marketed formulations, however, suggests that there is only a weak ass...
INDUSTRIAL AVAILABILITY With the monoclonal antibodies of the present invention, insulin can sensitively and specifically be assayed without being affected by proinsulin and insulin analogs. Since insulin secretion from the beta cells can be accurately monitored by the present invention, the present invent...